Pembrolizumab in relapsed or refractory Richter syndrome
journal contributionposted on 2020-12-18, 04:07 authored by P Armand, N Murawski, D Molin, J Zain, B Eichhorst, Z Gulbas, Eliza HawkesEliza Hawkes, JM Pagel, T Phillips, V Ribrag, J Svoboda, A Stathis, A Chatterjee, R Orlowski, P Marinello, B Christian
No description supplied
The authors thank the patients and their families, as well as investigators and site personnel. Medical writing and/or editorial assistance was provided by Cathy R. Winter, PhD, and Matthew Grzywacz, PhD, of the ApotheCom pembrolizumab team (Yardley, PA, USA). This assistance was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Funding for this research was provided by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
JournalBritish Journal of Haematology
Pagination4p. (p. e117-e120)
Rights StatementThe Author reserves all moral rights over the deposited text and must be credited if any re-use occurs. Documents deposited in OPAL are the Open Access versions of outputs published elsewhere. Changes resulting from the publishing process may therefore not be reflected in this document. The final published version may be obtained via the publisher’s DOI. Please note that additional copyright and access restrictions may apply to the published version.
CategoriesNo categories selected